Answers are grounded in this paper and cite their sources.
SUMMARY The AIDS epidemic greatly increased patients’ and the public’s fear of blood transfusion and resulted in major increased efforts to reduce the risk of transfusion‐transmitted diseases. Testing strategies have been very effective in reducing the risk of transfusion‐transmitted diseases. However, the current approaches have shortcomings: (i) they apply only to known pathogens and not to other presently unknown infectious agents; (ii) they are reactive to new transmissible diseases and thus accept that some patients may be harmed before preventive measures can be implemented; (iii) they do not prevent bacterial contamination; (iv) they do not prevent transmission of other known or unknown infectious agents; and (v) they result in an excessive loss of otherwise suitable donors. Several approaches have been developed to inactivate pathogen in cellular blood components and plasma. Two companies are developing methods that are highly effective for pathogen inactivation, and toxicities of the methods seem to be minimal and not of clinical importance. The in vitro function and in vivo effectiveness of pathogen‐inactivated platelets are clinically acceptable. These exciting developments raise the possibility of a paradigm shift in our approach to reducing the risk of transfusion‐transmitted diseases.
No takes yet. Share an insight, caveat, or question.
Jeffrey McCullough (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: